哮喘缓解:什么是哮喘缓解?如何实现哮喘缓解?

Dennis Thomas, V. McDonald, I. Pavord, P. Gibson
{"title":"哮喘缓解:什么是哮喘缓解?如何实现哮喘缓解?","authors":"Dennis Thomas, V. McDonald, I. Pavord, P. Gibson","doi":"10.1183/13993003.02583-2021","DOIUrl":null,"url":null,"abstract":"Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments. As we are moving through a new era of highly effective targeted biologics, macrolides and precision medicine in asthma management, it is logical to consider a paradigm shift in the treatment goals from asthma control to asthma remission https://bit.ly/3N9nEqN","PeriodicalId":77419,"journal":{"name":"The European respiratory journal. Supplement","volume":"84 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"33","resultStr":"{\"title\":\"Asthma remission: what is it and how can it be achieved?\",\"authors\":\"Dennis Thomas, V. McDonald, I. Pavord, P. Gibson\",\"doi\":\"10.1183/13993003.02583-2021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments. As we are moving through a new era of highly effective targeted biologics, macrolides and precision medicine in asthma management, it is logical to consider a paradigm shift in the treatment goals from asthma control to asthma remission https://bit.ly/3N9nEqN\",\"PeriodicalId\":77419,\"journal\":{\"name\":\"The European respiratory journal. Supplement\",\"volume\":\"84 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"33\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The European respiratory journal. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.02583-2021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European respiratory journal. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.02583-2021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 33

摘要

哮喘的治疗目标目前集中在症状和恶化控制,而不是缓解。缓解并不等同于治愈,但更接近于治愈。本综述考虑了哮喘缓解的当前定义、患病率和预测因素、缓解的病理生理学、使用现有治疗方案实现缓解的可能性以及未来的研究方向。哮喘缓解的特征是高水平的疾病控制,包括没有症状和恶化,以及在持续治疗或不治疗的情况下肺功能正常化或优化。即使在哮喘症状缓解的患者中,持续的病理异常也很常见,这导致了随后随时复发的风险。除了症状缓解外,完全缓解需要任何潜在病理的正常化或稳定。作为哮喘自然史的一部分,缓解是可能的,成人哮喘人群中缓解的患病率在2%至52%之间。与缓解相关的因素包括轻度哮喘、更好的肺功能、更好的哮喘控制、更年轻、早发哮喘、更短的哮喘持续时间、更轻微的支气管高反应性、更少的合并症和戒烟或从不吸烟。虽然以前的研究没有针对治疗诱导的缓解,但有一些证据表明,目前的长期附加疗法,如生物制剂和阿奇霉素,至少在一个亚组患者中,可以达到哮喘治疗缓解的某些标准。然而,还需要更多的研究。长期缓解可以作为哮喘治疗研究的一个治疗目标。随着我们在哮喘管理中进入高效靶向生物制剂、大环内酯类药物和精准医学的新时代,考虑治疗目标从哮喘控制到哮喘缓解https://bit.ly/3N9nEqN的范式转变是合乎逻辑的
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Asthma remission: what is it and how can it be achieved?
Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments. As we are moving through a new era of highly effective targeted biologics, macrolides and precision medicine in asthma management, it is logical to consider a paradigm shift in the treatment goals from asthma control to asthma remission https://bit.ly/3N9nEqN
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信